Benzinga | May 25, 2021 06:41AM EDT

Barclays Initiates Coverage On Conmed with Overweight Rating, Announces Price Target of $175

Barclays analyst Travis Steed initiates coverage on Conmed (NYSE:CNMD) with a Overweight rating and announces Price Target of $175.